MedMira receives Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for Point-of-Care use

Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from Health Canada for its Reveal® Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% […]
MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV

Halifax, Nova Scotia – December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and […]
U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player […]
MedMira receives CE mark for its VYRA™ CoV2Flu Antigen Test

Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received the CE mark and VYRA™ CoV2Flu is now available in […]
MedMira receives CE mark for its VYRA™ COVID-19 Antigen Test

Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), the fastest SARS-CoV-2 Antigen test available. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. MedMira […]